🔗 Share this article The United States and United Kingdom Establish Tariff-Free Arrangement on Medicines. Representative image of medicine exports. The UK and US have agreed to a major trade agreement that will maintain no tariffs on UK pharmaceutical exports entering the US market. The Terms of the Pact Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the public health system. This move guarantees that import taxes on these vital exports will be held at nothing for a period of the next three years. This agreement is in response to previous threats to hike duties on patented drug products, with potential rates mentioned as high as 100%. "This deal between the Britain strengthens the global environment for cutting-edge drugs and introduces much-needed fairness to U.S.–U.K. medicine commerce," a release noted. Economic Significance Medicines represent one of the UK's biggest goods shipped to the America, which is by far the biggest market for leading British pharmaceutical firms. Trade data show that in the one-year period prior to September, the UK sold drugs valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that span. "This agreement protects jobs, stimulates funding and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented. Key NHS Changes The deal involves several key changes from the UK: Price Threshold Increase: The UK will lift the cost ceiling at which it deems new treatments to be prohibitively costly by a quarter. Increased NHS Spending: There is a goal to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade. Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be capped at 15%. In the past, rebates topped 20%. Recent Tensions The pact comes amid a long-running dispute between the drug companies and the UK government over spending levels and NHS adoption. This friction were heightened by claims that American patients were charged a premium for the equivalent treatments than consumers in the UK and Europe. Recently, several significant pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward American operations. The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
Representative image of medicine exports. The UK and US have agreed to a major trade agreement that will maintain no tariffs on UK pharmaceutical exports entering the US market. The Terms of the Pact Under the terms of the agreement, the UK has agreed to boost spending on pharmaceuticals through the public health system. This move guarantees that import taxes on these vital exports will be held at nothing for a period of the next three years. This agreement is in response to previous threats to hike duties on patented drug products, with potential rates mentioned as high as 100%. "This deal between the Britain strengthens the global environment for cutting-edge drugs and introduces much-needed fairness to U.S.–U.K. medicine commerce," a release noted. Economic Significance Medicines represent one of the UK's biggest goods shipped to the America, which is by far the biggest market for leading British pharmaceutical firms. Trade data show that in the one-year period prior to September, the UK sold drugs valued at over eleven billion pounds to the US. This figure made up nearly one-fifth of British export trade in that span. "This agreement protects jobs, stimulates funding and paves the way for the UK to become a worldwide center for biotech and pharma," the Business and Trade Secretary commented. Key NHS Changes The deal involves several key changes from the UK: Price Threshold Increase: The UK will lift the cost ceiling at which it deems new treatments to be prohibitively costly by a quarter. Increased NHS Spending: There is a goal to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade. Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be capped at 15%. In the past, rebates topped 20%. Recent Tensions The pact comes amid a long-running dispute between the drug companies and the UK government over spending levels and NHS adoption. This friction were heightened by claims that American patients were charged a premium for the equivalent treatments than consumers in the UK and Europe. Recently, several significant pharmaceutical investments in the UK have been delayed or scrapped, while major funding commitments have been pledged toward American operations. The Science Minister acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.